Basic Information
TETAVAX single dose, suspension for injection in a prefilled syringe
SUSPENSION, STERILE
Regulatory Information
SIN13657P
June 16, 2009
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07AM01
Company Information
Active Ingredients
Strength: 40 I.U. / 0.5ml dose
Detailed Information
Contraindications
**4.3 Contraindications** The lethal risk associated with tetanus excludes any potential contraindication and imposes post-wound exposure prophylaxis In other cases: - Hypersensitivity to one of the ingredients of the vaccine. - Usual contraindications for all vaccinations: vaccination should preferably be postponed in case of fever, acute disease or chronic progressive illness. - Hypersensitivity reaction or neurological disorder after a previous injection of vaccine.
Indication Information
**4.1 Therapeutic Indications** Tetanus prevention and, in particular: - Post-exposure tetanus prophylaxis for recent wounds that may have been contaminated with tetanus spores in subjects who have not had any primary vaccination or for whom primary vaccination is incomplete or uncertain, - Neonatal tetanus prophylaxis in non-immunised women either of childbearing age or pregnant in countries where neonatal tetanus is frequent, - Primary vaccination, - Booster injections.